Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.41 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.41 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 3/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1694726 | 0.98 | YTHDF2 (0.40) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| SCHEMBL2587816 | 0.94 | DAO (0.38) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| Hydrochloric Acid SCHEMBL2595212 | 0.92 | DAO (0.37) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| SCHEMBL14727105 | 0.79 | DAO (0.39) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| SCHEMBL9887473 | 0.77 | YTHDF2 (0.44) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| SCHEMBL19620987 | 0.77 | KDM4E (0.39) | YTHDF2YTHDF3YTHDF1DAOGAA | |
| SCHEMBL1695218 | 0.74 | MAPK1 (0.46) | GAAKDM4EALDH1A1GRIN2DGRIN3B | |
| SCHEMBL1694829 | 0.73 | KDM4E (0.38) | DAOGAAKDM4EALDH1A1NR3C1 | |
| SCHEMBL27972990 | 0.73 | LMNA (0.39) | DAOGAAHSD17B10KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1694763 | 0.73 | MAPK1 (0.44) | GAAKDM4EALDH1A1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| EP-2755962-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2755962-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| CN-102970869-A | Indoles | GLAXOSMITHKLINE LLC | 2013-03-13 | — | — | CN | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | YTHDF2 1266/4885YTHDF3 2287/4885YTHDF1 1723/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | YTHDF2 1605/4885YTHDF3 1418/4885YTHDF1 1990/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | YTHDF2 1266/4885YTHDF3 2287/4885YTHDF1 1723/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | YTHDF2 1266/4885YTHDF3 2287/4885YTHDF1 1723/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | YTHDF2 1290/4885YTHDF3 1259/4885YTHDF1 1700/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | YTHDF2 1335/4885YTHDF3 1299/4885YTHDF1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.